mrd: venetoclax vs. btk-inhibitors for cll
Published 5 years ago • 335 plays • Length 1:30Download video MP4
Download video MP3
Similar videos
-
1:42
treating cll after venetoclax or btk inhibitors
-
1:27
advances in btk and bcl2 inhibitors for cll
-
1:11
treatment options for patients with cll after failure of covalent btk inhibitors and venetoclax
-
2:32
important factors to consider when selecting between venetoclax & btk inhibitors for cll
-
2:35
mrd determinations in venetoclax treatment of cll
-
1:24
sequencing of btk inhibitors in cll
-
0:55
the impact of mrd & genetics on outcomes to time-limited combinations in patients with cll
-
1:59
choosing the best btk inhibitor for managing cll
-
7:24
what are the current cll treatment options?
-
19:50
j.morita i-dixel demo
-
1:55
the evolving role of venetoclax in cll
-
1:48
maic of pirtobrutinib vs venetoclax in patients with r/r cll previously treated with a covalent btki
-
1:47
ash cll highlights: ibrutinib-venetoclax combination & undetectable mrd in ighv-mutated patients
-
4:21
hovon 141/vision trial update: mrd-guided venetoclax ibrutinib treatment for r/r cll
-
5:34
venetoclax added to ibrutinib in patients with cll with molecular resistance to btki treatment
-
1:33
the difficulties of mrd detection in dlbcl
-
1:53
achieving undetectable mrd with ibrutinib plus venetoclax for cll
-
1:27
finite therapies with the combination of btkis and venetoclax in cll
-
1:05
btk degraders in the treatment of cll
-
2:36
mrd-driven addition of ibrutinib to venetoclax for cll
-
2:17
uk ncri flair trial: ibrutinib venetoclax with mrd-directed duration of treatment in cll
-
1:35
the in-depth responder analysis from phallcon: ponatinib versus imatinib